In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

肺癌是全球癌症死亡的首要原因。即使接受了完全切除手术，NSCLC患者术后复发率仍然很高。目前的国际指南（如NCCN、ESMO等）推荐的术后随访策略过于“一刀切”，没有考虑不同患者的复发风险差异。本研究希望基于10年随访数据，提出一个更个性化、部位特异 ...

MET 14 号外显子跳跃突变（MET 14 跳变）是非小细胞肺癌（NSCLC）的少见驱动基因。携带 MET 14 跳变的患者对传统治疗反应不佳，随着 MET 酪氨酸激酶抑制剂（TKI）的问世，患者终于迎来精准靶向治疗选择。目前，MET-TKI ...

随着系统性治疗效果的提升，ALK 阳性晚期肺癌患者的生存期显著延长。其中部分患者可能会出现「寡进展」，请问汪教授，您认为外科干预在这些患者的全程管理中应如何定位？在决定是否进行局部治疗时，多学科诊疗（MDT）讨论有何重要作用？

Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this ...

When treated with KRAS inhibitors alone, cancer cells can escape destruction by using the salvage pathway to gather ...

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

Non-small cell lung cancer (NSCLC) remains the most prevalent type of lung cancer and a leading cause of cancer-related mortality worldwide. Surgical ...